StreetInsider.com News Articles

Form 10-K Invivyd, Inc. For: Dec 31

Thu, 05 Mar 2026 07:21:00 -0500

si-local-file:///var/storage/secattach/20260305/26115043.html

Form 10-K Invivyd, Inc. For: Dec 31

Thu, 05 Mar 2026 07:21:00 -0500

si-local-file:///var/storage/secattach/20260305/26115043.html

Form 8-K Invivyd, Inc. For: Mar 05

Thu, 05 Mar 2026 07:12:00 -0500

si-local-file:///var/storage/secattach/20260305/26115004.html

Form 8-K Invivyd, Inc. For: Mar 05

Thu, 05 Mar 2026 07:12:00 -0500

si-local-file:///var/storage/secattach/20260305/26115004.html

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Thu, 05 Mar 2026 07:03:00 -0500

Achieved Q4 2025 PEMGARDA^® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025
DECLARATION trial on track with full enrollment achieved
DECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC recommendation to allow enrollment of pregnant and

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Thu, 05 Mar 2026 07:03:00 -0500

Achieved Q4 2025 PEMGARDA^® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025
DECLARATION trial on track with full enrollment achieved
DECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC recommendation to allow enrollment of pregnant and

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Thu, 05 Mar 2026 07:03:00 -0500

Achieved Q4 2025 PEMGARDA^® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025
DECLARATION trial on track with full enrollment achieved
DECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC recommendation to allow enrollment of pregnant and

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Thu, 05 Mar 2026 07:03:00 -0500

Achieved Q4 2025 PEMGARDA^® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter
2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025
Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025
DECLARATION trial on track with full enrollment achieved
DECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC recommendation to allow enrollment of pregnant and

Invivyd names Michael Mina as chief medical officer

Thu, 05 Mar 2026 07:01:30 -0500

Invivyd Inc. (NASDAQ: IVVD) appointed Michael Mina, M.D., Ph.D., as chief medical officer, the biopharmaceutical company announced.

Mina previously served as assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. He has also held chief science or chief medical officer positions at several diagnostics and digital health companies.

During the COVID-19 pandemic, Mina advised U.S. federal and international governments on testing policies and helped lead the U.S. government's Home Test-to-Treat Program, which focused on improving treatment access for underserved populations for influenza and

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Thu, 05 Mar 2026 07:01:00 -0500

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina strengthens Invivyd’s medical leadership
Dr. Mina’s research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipeline
With more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Thu, 05 Mar 2026 07:01:00 -0500

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina strengthens Invivyd’s medical leadership
Dr. Mina’s research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipeline
With more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Thu, 05 Mar 2026 07:01:00 -0500

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina strengthens Invivyd’s medical leadership
Dr. Mina’s research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipeline
With more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Thu, 05 Mar 2026 07:01:00 -0500

Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, Dr. Mina strengthens Invivyd’s medical leadership
Dr. Mina’s research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipeline
With more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mon, 02 Mar 2026 16:10:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update.

Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mon, 02 Mar 2026 16:10:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update.

Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mon, 02 Mar 2026 16:10:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update.

Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Mon, 02 Mar 2026 16:10:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update.

Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 02 Mar 2026 16:01:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.69, representing the closing price of Invivyd’s common stock on February 27, 2026, the last trading

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 02 Mar 2026 16:01:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.69, representing the closing price of Invivyd’s common stock on February 27, 2026, the last trading

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 02 Mar 2026 16:01:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.69, representing the closing price of Invivyd’s common stock on February 27, 2026, the last trading

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 02 Mar 2026 16:01:00 -0500

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on March 1, 2026, Invivyd granted four newly hired non-executive employees options to purchase an aggregate of 192,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $1.69, representing the closing price of Invivyd’s common stock on February 27, 2026, the last trading

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Tue, 24 Feb 2026 07:01:00 -0500

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy
This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding to prior work demonstrating similar relationships from the pandemic era
Model-derived estimates align with observed infection outcomes and external analyses including work with prior Invivyd and other COVID mAbs, supporting model validity and variant-agnostic protection from COVID

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Tue, 24 Feb 2026 07:01:00 -0500

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy
This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding to prior work demonstrating similar relationships from the pandemic era
Model-derived estimates align with observed infection outcomes and external analyses including work with prior Invivyd and other COVID mAbs, supporting model validity and variant-agnostic protection from COVID

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Tue, 24 Feb 2026 07:01:00 -0500

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy
This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding to prior work demonstrating similar relationships from the pandemic era
Model-derived estimates align with observed infection outcomes and external analyses including work with prior Invivyd and other COVID mAbs, supporting model validity and variant-agnostic protection from COVID

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Tue, 24 Feb 2026 07:01:00 -0500

“A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy
This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multiple Omicron-virus variants in a modern, COVID-endemic, seropositive population, adding to prior work demonstrating similar relationships from the pandemic era
Model-derived estimates align with observed infection outcomes and external analyses including work with prior Invivyd and other COVID mAbs, supporting model validity and variant-agnostic protection from COVID